Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Avexa completes recruitment for first component of phase III trial of apricitabine

Nov. 26, 2008

Theratechnologies completes treatment of patients in extension phase of tesamorelin trial

Nov. 18, 2008

Genetic Immunity doses first patient in phase II DermaVir Patch trial for HIV

Nov. 17, 2008

Novel NNRTIs reported by Roche

Nov. 12, 2008

Interim data show feasibility of i.v., s.c. PRO-140 for HIV

Nov. 6, 2008

First-in-human study of HIV protease inhibitor SPI-256 completed

Nov. 5, 2008

Novel anti-HIV agents disclosed in recent patent literature

Nov. 5, 2008

EMD Serono and Theratechnologies collaborate for tesamorelin in the U.S.

Oct. 30, 2008

Bevirimat achieves plasma levels in target range for virologic reduction in HIV

Oct. 29, 2008

TRI-1144 well tolerated in healthy subjects

Oct. 29, 2008

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026